Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Johnson & Johnson Innovation – Jjdc
AddedFeb 13, 2024
UpdatedJul 16, 2026
Johnson & Johnson Innovation – Jjdc

Johnson & Johnson Innovation – Jjdc

Operating

Johnson & Johnson Innovation, based in Cambridge, MA, accelerates early-stage innovation across healthcare sectors.

Location
Cambridge, MA, US
Founded
1973
Firm
Compare
Portfolio
Employees

Investments

SonoThera
SonoThera
Series B

Total Raised

$185.8M

Rounds

2

Series B$125MJune 2026
Series A$60.8MDecember 2022
Accent Therapeutics
Accent Therapeutics

Total Raised

$178M

Rounds

3

Series C$75MJanuary 2024
Aro Biotherapeutics
Aro Biotherapeutics

Total Raised

$166.5M

Rounds

4

Series B$41.5MNovember 2023
On Target Laboratories
On Target Laboratories

Total Raised

$111.7M

Rounds

6

Series C$30MNovember 2023
RefleXion Medical
RefleXion Medical

Total Raised

$675.1M

Rounds

11

Series Unknown$105MNovember 2023
Series Unknown$80MMarch 2022
Jurata Thin Film
Jurata Thin Film

Total Raised

$4.9M

Rounds

3

GrantSeptember 2023
Arialys Therapeutics
Arialys Therapeutics

Total Raised

$58M

Rounds

1

Seed$58MSeptember 2023
Rome Therapeutics
Rome Therapeutics

Total Raised

$199M

Rounds

3

Series B$72MSeptember 2023
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Series A$100MMarch 2023
Solenic Medical
Solenic Medical

Total Raised

$7.3M

Rounds

6

Series A$5.1MJune 2023
Perceive Biotherapeutics
Perceive Biotherapeutics

Total Raised

$78M

Rounds

1

Series B$78MJanuary 2023
HistoSonics
HistoSonics

Total Raised

$226.8M

Rounds

10

Convertible Note$85MDecember 2022
DocSpera
DocSpera

Total Raised

$10M

Rounds

2

Series B$10MSeptember 2022
TRex Bio
TRex Bio

Total Raised

$85M

Rounds

2

Series A$26MMarch 2022
Rondo Therapeutics
Rondo Therapeutics

Total Raised

$67M

Rounds

1

Series A$67MMarch 2022
Iterative Scopes
Iterative Scopes
Series B

Total Raised

$193.6M

Rounds

11

Series B$150MJanuary 2022
Series A$30MAugust 2021
Verana Health
Verana Health

Total Raised

$288.8M

Rounds

5

Series E$150MJanuary 2022
FlexDex
FlexDex
Public

Total Raised

$37.8M

Rounds

7

Series Unknown$13MAugust 2021
Visus Therapeutics
Visus Therapeutics

Total Raised

$56M

Rounds

2

Series B$20MAugust 2021
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series C$65MJune 2021
Thirty Madison
Thirty Madison

Total Raised

$228.3M

Rounds

5

Series C$140MJune 2021